2024-09-01 - Analysis Report
##  ABBV Stock Analysis Report

**Company Overview:** AbbVie Inc. (ABBV) is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription drugs.

**Performance Analysis:**

**1. Performance against S&P 500 (VOO):**
* **Cumulative Return:** ABBV (106.38%) has outperformed VOO (89.66%) significantly. 
* **Relative Divergence:** The current relative divergence is 48.47, indicating that ABBV is currently outperforming VOO. The relative divergence sits at the 88.69 percentile of historical divergence values, implying that ABBV's current performance against VOO is strong compared to its historical performance.

**2. Recent Price Movements:**
* **Closing Price:** $196.31
* **5-Day Moving Average:** $196.05
* **20-Day Moving Average:** $193.17
* **60-Day Moving Average:** $179.48
* **Analysis:** ABBV's recent price movements indicate a short-term upward trend, with the closing price above all three moving averages.

**3. Technical Indicators:**
* **RSI:** 74.27 -  The RSI is currently in the overbought territory, suggesting that the stock may be due for a correction in the short term.
* **PPO:** -0.36 - The PPO is negative, suggesting a potential for a slight price pullback.
* **Delta_Previous_Relative_Divergence:** 10.4 - The positive change in relative divergence indicates a short-term upward trend.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

**Analysis:**
* ABBV has consistently exceeded earnings expectations in recent quarters, demonstrating strong profitability and growth. 
* The most recent earnings report shows EPS of 2.65, exceeding the expected EPS of 2.57. 

**Overall Analysis:**

ABBV exhibits a strong track record of performance, outperforming the broader market (VOO) consistently. Recent price movements suggest an upward trend, while technical indicators point towards potential short-term corrections. The company's robust earnings performance reinforces the positive outlook. However, the RSI being in overbought territory suggests a possible short-term price pullback. Overall, ABBV remains a promising investment opportunity with strong fundamentals and growth potential. 
